MEDIUMResearchTier 1

Local Sodium Tanshinone IIA Sulfonate Attenuates Periodontal Bone Loss by Modulating Inflammatory, Immune and Osteoclastogenic Signalling

SourceJournal of Clinical PeriodontologyTier 1Peer-Reviewed Research

By Rafael Scaf de Molon, Raquel Mantuaneli Scarel‐Caminaga, François Isnaldo Dias Caldeira, Edilson Ervolino, Erica Dorigatti de Avila, Paula Aboud Barbugli, Gabriela Ezequiel Oliveira, Joao Pedro Franco‐Moura, Leticia Helena Theodoro, Joni Augusto Cirelli, Sotirios Tetradis, Alpdogan Kantarci

Originally at onlinelibrary.wiley.com

Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.

Why it matters for dental

Periodontal practices and specialists may soon have a new adjunctive therapy to reduce alveolar bone loss by targeting inflammatory and osteoclast pathways, potentially changing non-surgical and surgical perio protocols.

Key points

  • Study published in Journal of Clinical Periodontology, Volume 53, Issue 9, September 2026, pages 1443-1458.
  • Sodium Tanshinone IIA Sulfonate applied locally modulates inflammatory cytokines, immune cell activity, and RANKL-mediated osteoclastogenesis.
  • Demonstrates statistically significant attenuation of periodontal bone loss in pre-clinical models.
  • Suggests potential for future localized drug-delivery adjuncts in periodontitis treatment.

Who should care

SpecialistAcademia

Read the original on Journal of Clinical Periodontology

Full reporting and any paywall content live on onlinelibrary.wiley.com. We summarize and score; we do not republish.

Open original

Related